Outcome of Board Meeting - Appointment of Company Secretary and Compliance Officer
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors at their Meeting held on February 02, 2017 have approved the appointment of Mr. Harish Kuber as the Company Secretary and Compliance Officer of the Company with effect from February 02, 2017 upon the recommendation of the Nomination and Remuneration Committee. Announces Q3 results (Standalone & Consolidated), Limited Review Report (Standalone & Consolidated), Management Discussion & Analysis & Results Press Release for the Quarter ended December 31, 2016
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter ended December 31, 2016:The Un-audited Standalone results for the Quarter ended December 31, 2016The Company has posted a net profit of Rs. 7113.07 million for the quarter ended December 31, 2016 as compared to Rs. 2631.76 million for the quarter ended December 31, 2015. Total Income has increased from Rs. 14132.80 million for the quarter ended December... Details of Earnings Call
Glenmark Pharmaceuticals Ltd has informed BSE regarding "Details of Earnings Call slated for February 03, 2016". Glenmark gets tentative approval from USFDA for Olmesartan
Glenmark has received tentative approval from the USFDA to sell Olmesartan Medoxomil tablets, which are used to treat high-blood pressure in patients. This is the generic equivalent of the drug sold under the brand name of Benicar in the US by Daiichi Sankyo. Q3 results on Feb 02, 2017
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on February 02, 2017, to consider and approve the Company's Unaudited Financial Statements for the Third Quarter and Nine months ended December 31, 2016 (Q3).Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors... Shareholding for the Period Ended December 31, 2016
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Glenmark Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Presentation
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the presentation that will be made at the J. P. Morgan Healthcare Conference, San Francisco, USA, the same will also be made available on the Company's website. Glenmark Pharmaceuticals: Making a mark - Buy
Healthy growth in major markets and focus on key therapies are positives Sanofi sues Glenmark, Torrent over sclerosis drug
Sanofi had received letters from Torrent and Glenmark, with a notice of their new drug applications